Meeting of the Transparency Council No. 48/2022 of 05.12.2022 r. – UPDATED

The agenda includes:

Preparation of an opinion on a model for the organisation of outpatient care for patients with chronic kidney disease.

Preparation of an opinion on a comprehensive amendment to create a new content for the drug programme B.56. “Treatment of patients with malignant neoplasm of prostate (ICD-10: C61)”.

Preparation of positions on the evaluation of drugs:

• Zeposia (ozanimod) under drug programme B.55. “Treatment of patients with ulcerative colitis (UC) (ICD-10: K51),
• Cibinqo (abrocitinib) under the drug programme “Treatment of patients with moderate to severe atopic dermatitis (ICD-10 L 20)”,
• Synagis (palivizumabum) under drug programme B.40. “Prevention of RS virus infection (ICD-10 P 07.2, P 27.1)”.

Preparation of an opinion on the assessment of the appropriateness of changing the reimbursement availability category for medicinal products containing the active substance lenalidomide.

Information on the previous agenda can be found HERE